Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization - Total (2016 - 2020)

Ani Pharmaceuticals' Depreciation & Amortization - Total history spans 9 years, with the latest figure at $1.3 million for Q4 2020.

  • For Q4 2020, Depreciation & Amortization - Total rose 8.33% year-over-year to $1.3 million; the TTM value through Sep 2021 reached $1.3 million, down 72.34%, while the annual FY2025 figure was $8.9 million, 20.27% up from the prior year.
  • Depreciation & Amortization - Total for Q4 2020 was $1.3 million at Ani Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $1.3 million in Q4 2020 and bottomed at $200000.0 in Q1 2016.
  • The 5-year median for Depreciation & Amortization - Total is $500000.0 (2018), against an average of $670000.0.
  • The largest annual shift saw Depreciation & Amortization - Total changed 0.0% in 2016 before it surged 300.0% in 2019.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $200000.0 in 2016, then soared by 50.0% to $300000.0 in 2017, then skyrocketed by 166.67% to $800000.0 in 2018, then soared by 50.0% to $1.2 million in 2019, then increased by 8.33% to $1.3 million in 2020.
  • Per Business Quant, the three most recent readings for ANIP's Depreciation & Amortization - Total are $1.3 million (Q4 2020), $1.1 million (Q3 2020), and $1.2 million (Q2 2020).